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The focus of this study is the effect of a laboratory analysis and socio-economic 
variables on choosing medical actions in a specific situation (a clinical vignette – a 
young woman, Mrs Hansen, with dyspepsia – presented to GPs). We assume that 
the GP’s decision depends on what he or she thinks is best for the patients, based 
on the best clinical evidence available. Significant variables associated with the 
choice of medical actions are: the result of the Helicobacter pylori (HP) test, the 
GP’s stated importance of HPRT, the location of the general practice, the GP 
recommending sick leave, the GP’s stated probability that Mrs Hansen’s 
symptoms are due to a H.pylori infection after the HP-result is known, and how 
the GP follows up the patient. Our results show that the HP-analysis has a 
significant and major influence on the GPs choice of medical actions. Therefore 
the quality of the analysis is likely to affect the patients’ health and social costs. 
Hence institutions for quality monitoring and improvement are important  
elements of health care reforms. Such institutions should balance cost and benefits 
of quality improving measures, and will be the focus of closer studies  
in our future research.     2
1. Introduction  
Laboratory tests have been analysed for many years in general practice (family 
medicine) in Norway. Laboratory tests are essential in diagnostic work-up and 
monitoring of patients. 
Compared with other European countries like Denmark and England, vast amounts 
of laboratory analyses in general practice are carried out decentralised in Norway, 
due in part to geographical factors and economic incentives. In Norway about 
1800 surgeries have laboratory facilities run by general practitioners (GPs), 
serving a population of 4.5 million.   
Our study was designed to develop a method for economic evaluation of near 
patient tests, using data from a questionnaire designed in cooperation with 
NOKLUS (The Norwegian Quality Improvement of Laboratory Services in 
Primary Care). NOKLUS is an organization that was established in 1992, and is 
funded by the Norwegian Medical Association's Fund for Quality improvement of 
laboratory services in primary care. At present, 99% of general practices 
participate on a voluntary basis in NOKLUS in order to improve the analytical 
quality of laboratory tests. However it is not enough that these tests are analysed 
correctly, it is just as important that tests are requested appropriately and 
interpreted correctly.  
In this paper, our main purpose is to study the effect of a test result with regard 
to medical actions taken. Previously (in an unpublished paper) we have studied the 
effect of certain characteristics on the two questions: whether to have or whether 
to use a specific laboratory analysis. Our next study will be a cost-benefit analysis   3
of good quality of a laboratory test, but this will only be relevant if the result of the 
test has a significant influence on the GP’s choice.  
A questionnaire including a clinical vignette, describing a 30-year old woman 
with dyspepsia, is used to assess the clinical reasoning and decisions made by GPs 
who had the Helicobacter pylori rapid test (HPRT) available in their surgery, and 
by a random sample of GPs who did not have HPRT in their surgery. By using a 
vignette we are able to focus on a relevant and standardized clinical situation 
familiar to the GP. In addition, we obtained information on the socio-economic 
characteristics of all the participants.  
The bacterium Helicobacter Pylori (H.pylori) can induce peptic ulcers, and is 
the main cause of this disease. HPRT is a simple test kit for single use, on to which 
a drop of blood is applied to test for the presence of antibodies to this bacterium. 
The advantage of having the test is that the GP can get the result of the test 
immediately, during the consultation. In contrast, if the GP sends a blood sample 
for serological testing, it takes 3-4 days to get the result, and this usually demands 
more follow-up by the GP. The presence of antibodies is often associated with the 
presence of viable bacteria in the stomach, but not always, since antibodies persist 
for months after the bacteria have been eradicated e.g. by antibiotics.  
  There are many laboratory tests available, and the reasons for choosing the HP 
test were several: it is a fairly new test, it can be carried out both as a rapid test and 
as an ordinary “hospital laboratory” test, it may be a crucial test in that other 
laboratory tests are not needed, and there are more complex procedures or gold 
standards available to evaluate the benefit (predictive value) of the test. 
Information about H.pylori is from Atherton et al (1) and Friedman (2).    4
Upper endoscopy is the definitive examination if the GP suspects peptic ulcer, 
because one can detect whether the bacteria have done any damage to the stomach 
or duodenum, as well as detecting the presence of H.pylori bacteria. The presence 
of viable bacteria (but not an anatomical diagnosis) is also substantiated by the so-
called breath test (a liquid swallowed by the patient is transformed by the bacteria, 
and this transformation is detected by measurements in the patient’s expired air). 
In this paper we use Discrete Choice Analysis with Multinomial logit models 
to analyse the choice of medical action among the GPs using this laboratory test to 
assess the patient, either by the rapid test or the serological (“hospital”) test. We 
assume that the GP’s decision depends on what he or she thinks is best for the 
patients, based on the best clinical evidence available to the GP. But the decision 
can also be influenced by the GP’s workload, and this will be further discussed in 
section eight.  
The GPs chose many different sets of medical actions and we grouped them by 
medical conclusions: 
-wait and see strategy, i.e. relieving symptoms by issuing prescriptions 
(Balancid/Zantac which reduce acid production in the stomach), hoping that the 
dyspepsia would not return after treatment,  
-further diagnostic measures i.e.referring for breath test or upper endoscopy, 
with or without symptomatic treatment,  
-immediate treatment by the so-called triple therapy (two antibiotics combined 
with a drug which abolishes the acid production in the stomach) in order to 
eradicate the H.pylori bacteria if present, but without further diagnostic 
measures. Here we include every GP who had recommended triple therapy. If   5
they also had used referrals, we assume that many of these examinations will 
probably not be done if the triple therapy was successful.  
For GPs who have the rapid test, variables with a positive significant effect on the 
probability of choosing referral vs. Balancid/Zantac are: a positive result on the 
rapid test, a high point (on a scale from 1 to 10) of the relative importance of 
HPRT, and whether the GP refrains from following up the patient either by 
making a new appointment or asking the patient to make a new appointment if she 
did not improve. Variables with a significant positive effect on the probability of 
choosing triple therapy vs. Balancid/Zantac are: a positive result of HPRT and 
whether the GP recommended sick leave. For GP’s without HPRT, a positive 
result of the laboratory analysis had a significant positive effect on choosing 
referral or triple therapy vs. Balancid/Zantac, and location in an urban area had a 
significant positive effect for choosing referral vs. Balancid/Zantac.  
  To our knowledge, there are no other studies on the significance of how the 
H.pylori analysis and the characteristics of the general practitioner affect the 
choice of medical actions in primary health care.  
  Our results show that the H.Pylori - analysis has a significant and a major 
influence on the GP’s choice of medical actions. We therefore conclude that the 
quality of the laboratory test is likely to have an effect on patients’ health and 
social costs, and hence that institutions for quality monitoring and improvement 
are important elements of health care reforms. Such institutions should balance 
cost and benefits of quality improving measures, and will be the focus of closer 
studies in our future research.     6
 
2. The survey, the H.pylori bacterium, and the analysis  
The focus of this study is the effect of the laboratory analyses and socio-economic 
variables on choosing medical actions in a specific situation. In this section we 
will focus on information about the survey and on the specific laboratory analysis 
in question.  
 
The survey 
The data used in this paper are based on a questionnaire (appendix A) mailed to 
GPs in April/May 1999. We had two sets of questionnaires, one set to all the GPs 
(n=739) who had HPRT in their surgery, and a different set to a random sample 
(n=717) of GPs who did not have HPRT in their surgery. The response rate was 
after one reminder 57% in both groups. To the GPs with HPRT, the questions 
depended on whether they chose to use the test or not in a given situation. In the 
questionnaire, a clinical vignette, describing a 30-year old woman with dyspepsia, 
was used to assess the clinical reasoning and decisions made by general 
practitioners. The clinical vignette describes a clinical situation fairly familiar to 
the GP, and in fact, with some modifications, this case history depicts a real 
patient. It was chosen from the medical record notes of consultations in which GPs 
had ordered the near patient test in real life. Minor modifications were made in 
collaboration with several clinicians (GPs and a gastroenterologist) and a 
microbiology specialist. It was an important element of the vignette that additional 
tests should not be necessary.    7
  In the questionnaire the GPs were asked to state: 
-  the pre-test probability that Mrs. Hansen's symptoms were caused by 
H.pylori 
-  whether or not they would order HPRT or the serological test 
-          what actions they would take based on the history, or on the history in 
addition to the             test result. 
In this study we focus on the effect of the H.pylori analysis, and therefore only 
include data from the GPs who ordered HPRT or the serological test. 
The actions (more than one could be chosen, and in addition, there was some 
open space for comments) 
1. - lifestyle advice 
2. - recommend locally-acting antacids (Balancid etc.) 
3. - try H2 antagonists (Zantac etc.) (more potent antacids) 
4. - try triple therapy 
5. - refer for breath test 
6. - refer for upper endoscopy 
7. - recommend sick leave 
8. - set up a new appointment 
9. - new appointment initiated by the patient 
In addition to the medical actions mentioned above, GPs without HPRT could 
choose to send a blood sample to a medical lab for serological testing. We also 
obtained information on the characteristics of all the GPs.    8
  The GPs later received feedback reports on their answers compared with the 
other GPs and with clinical guidelines about the use of the H.pylori analysis 
relevant to our patient.  
   
The dependent variables  
We reduced the alternative actions as follows: 
-  “lifestyle advice” was given by nearly everyone, and we therefore did not 
consider this alternative as a medical action 
-  “sick leave” (alt. 7) and “new appointment” (alts. 8 and 9) are coded as 
characteristics of the GP because whether or not a GP chose to give a patient sick 
leave or make a new appointment are somewhat related to the personality and 
practice style of the GP. Here we don’t have any input from the patient. But we 
also believe that these variables are influenced by the alternatives chosen. This is 
further discussed in section five. 
When grouping the different sets of medical actions we focuse on alternatives two 
to six.  
The GP could choose conservative treatment, either antacids or histamine 
antagonists. To cure an H.pylori infection he could choose to try triple therapy. 
Two-week triple therapy reduces ulcer symptoms, kills the bacteria and prevents 
ulcer recurrence in more than 90% of patients.  
An endoscopy is carried out as an ambulatory service in hospitals or by 
practicing gastroenterologists and is an examination that uses an endoscope, a thin, 
lighted tube with a tiny camera on the end. The patient is lightly sedated, and the 
doctor eases the endoscope into the mouth and down the throat to the stomach and   9
duodenum. This allows the doctor to see the lining of the oesophagus, stomach, 
and duodenum. The doctor can use the endoscope to take photos of ulcers and 
remove a tiny piece of tissue to view under a microscope to see if the bacteria have 
done any damage.  
 
More about the H.pylori bacterium and the H.pylori analysis 
H.pylori analysis detects antibodies to the H.pylori bacterium. The result of the 
laboratory test is read as negative or positive, and the cut-off point is similar for 
both for the rapid test and ordinary serology. If the result is positive it means that 
there are antibodies to H.pylori in the blood. The problem is that many of those 
who have antibodies do not have a peptic ulcer and do not need any treatment. 
Even in younger people the prevalence of the bacteria may be as high as 15%. 
Serological testing is more accurate than HPRT because it has a higher 
sensitivity (95% versus 85%) and specificity (95% versus 80%) for detection of H 
pylori. The sensitivity of the test is here the probability of getting a positive result 
if the patient has viable bacteria in the stomach, and the specificity of the test is the 
probability of a negative result if the patient does not have H.pylori bacteria. 
   
3. Hypotheses  
We are interested in studying the impact of laboratory tests on clinical decision-
making. Hence, in this section we concentrate on the characteristics of the 
information derived from laboratory testing and how this information is likely to 
be used in determining clinical actions. We also introduce some other variables   10
that are included as control variables in the empirical analyses. Hypotheses are 
derived under the assumption that decisions are motivated by serving patients’ best 
interests. This motivation is further discussed in the concluding remarks. 
   The pre-test probability is the GP’s assumption that the patient in our case 
history had an H.pylori infection as the cause of her dyspepsia before the HP-test 
was taken, and the post-test probability is the GP’s assumption that the patient had 
an H.pylori infection taking the test result into account. The post-test probability 
depends on the GP’s pre-test-probability and the result of the HP-test. If the test 
result is positive this means that a GP with a pre-test-probability of 30% should 
state a post-test-probability of H.pylori caused dyspepsia (i.e. ulcer) of 55% if 
HPRT is used, and 69% if a serological test is used, because the serological test is 
better than HPRT (from calculations in the feed-back report to the GPs on the 
questionnaire). According to clinical guidelines, the GP can choose between 
referral or prescription of triple therapy. If the test is negative there is a probability 
of over 90% that the patient does not have an H.pylori infection, and the symptoms 
are probably only temporary and the GP should prescribe Balancid/Zantac. 
We assume that if the GP has a low pre-test and a low post-test-probability, the GP 
will choose only to give Balancid or Zantac. We also expect that the importance of 
the pre-test- and post-test-probability in the diagnostic decision-making is non-
linear and that the importance of the probability increases with the pre-test and the 
post-test value. We assume that each GP generally has his own threshold value of 
a patient’s probability of having an H.pylori infection, and above this threshold 
value the probability curve is steep. The exception is when the pre-test or post-test 
probability is very high; then the GP feels confident of the diagnosis. We test this   11
hypothesis by including a squared pre-test variable or a squared post-test variable 
that we assume is negative.  
GPs with HPRT were asked to distribute 10 points between the case history, 
clinical findings, and the laboratoryresult, allotting a higher number of points with 
increasing importance. We assume that the GPs who allotted a relatively high 
score to the importance of the HP-test will tend to choose triple therapy if the test 
is positive, and Balancid or Zantac if the test is negative.  
Referral to upper endoscopy will be more inconvenient for the patient if the 
waiting time or the travelling time is long, and thus we assume that the probability 
of referral to upper endoscopy decreases in step with the travelling time or waiting 
time.  
  The GPs who prefer to follow up the patient may choose medical actions that 
demand more follow-up. Only prescribing Balancid/Zantac demands more follow-
up by the GP than referring the patient for a breath test or upper endoscopy. We 
assume therefore that the GPs who follow up their patient by making a new 
appointment or asking the patient to make a new appointment tend to give 
Balancid/Zantac versus referral or the triple therapy.  
The probability of meeting a patient with symptoms indicating peptic ulcer 
increases with the number of patients, and hence with the number of consultations 
and working hours. And we want to study whether GPs with more experience 
(high number of consultations and working hours) would choose differently from 
GPs with less experience.  
GPs in group practices have the same type of laboratory equipment. We assume 
that the GPs influence each other in discussions about what kind of lab-equipment   12
the practice should have, and as a consequence of more inter-collegiate exchange 
of information, they are more aware of its weaknesses and less apt to give triple 
therapy than GPs in solo practices. 
General practices in urban areas face competition for patients, and one way of 
getting a competitive advantage is to give quicker service to the patients. We 
assume therefore that, compared to GPs located in urban and semi-urban areas, 
GPs in the cities have a higher probability of choosing referral or prescribing triple 
therapy versus Balancid/Zantac.  
The GPs who only use supplier's information as the most important information 
source regarding the use of HPRT are those who have used information from visits 
by a supplier, exhibitions, mailed information, or other types of information from 
the suppliers. GPs with “other combinations” have used "The Journal of the 
Norwegian Medical Association", courses or other sources. We want to study 
whether the fact that GPs only use supplier’s information or not affects their 
choice of medical action. 
A number of courses are required in order to maintain a specialist certificate, 
and we want to study whether the GP’s education affects his or her choice of 
medical action. 
Primary health care is the responsibility of the municipalities. We collected our 
data in April/May 1999 and our description is based on the type of payment 
system we had then. About 2/3 of the doctors in general practices were self-
employed, and their income derived from three sources: a fixed grant from the 
municipality, patient co-payment, and reimbursement from the National health 
Insurance according to a negotiated tariff (about 1/3 each). Some of the doctors did   13
not have an agreement with the municipality, but could use the same National 
health Insurance Reimbursement tariff and usually charge a higher patient co-
payment. We had three types of payment in private practice: GPs with fee-for-
service combined with a practice allowance from the municipalities, GPs with only 
fee-for-service, and list-doctors. A new doctor organisation in general practice 
based on a list system had been tried out in 4 municipalities since 1993. These 
doctors get an annual fee for each patient on their list (per capita fee) from the 
municipality. In addition they got fee-for-service based on a special tariff. From 
June 2001 the list system is enacted as the system by which primary health care is 
organised in Norway, but it is still possible to be on a fixed salary rather than per 
capita and fee-for-service.  
The last group is GPs who receive a fixed salary from the municipality. The 
municipality also pays the salaries for other personnel in the practice and other 
costs of running the practice. This is the only group that does not receive fee-for-
service financing. For GPs on fixed salary the doctor’s salary is independent of the 
income and expenses in the practice. We include whether the GP is in private 
practice as a control variable in the empirical analysis, without having any 
particular hypothesis regarding the effect of private practice on clinical decision- 
making in this particular case.  
 
4. Data  
In this section we will first give an overview of the available choices the GP had in 
according to our questionnaire (figure 1), or had made before we sent out the   14
questionnaire (i.e. the decision to have HPRT available). Afterwards we will give 
an overview of what the GPs chose as medical actions (the dependent variables), 
and an overview of the independent variables.  
For GPs with HPRT we study the choice made in the first consultation in those 
who used HPRT. For GPs without HPRT it is in the second consultation that they 
chose medical actions, depending on the result of the serological test. In the first 
consultation they chose to use a serological test in addition to the medical actions. 
In the second consultation the patient returns after two weeks and is not feeling 
better. 
We cannot compare GPs with and without HPRT directly, because for GPs with 
HPRT we study the medical actions chosen in the first consultation, while for GPs 
without HPRT, we study the medical actions chosen in the second consultation. In 
the second consultation GPs have  
received more information than GPs with HPRT since they know that the medical 




The dependent variables  
The GPs chose many different sets of medical actions and we grouped them by 
medical decisions into three categories as described in the introduction: 
- Balancid/Zantac  
- Referrals   
- Triple therapy.    15
Table 1 shows an overview over the number of GPs who had chosen the different 
medical strategies, depending on the result of the HP-test. If a GP without HPRT 
in the first consultation referred the patient for a breath test or an upper endoscopy, 
we anticipate that it has not yet been done by the second consultation. We grouped 
the medical actions in both consultations concerning GPs without HPRT, because 
we wanted to study if the medical actions in the first consultation would influence 
their choices in the second.  
TABLE 1 
 
Table 1 shows that the GPs’ choices of medical actions depend on the result of the 
HP-test, and follow clinical guidelines, given that the lab.result is correct. When 
the lab result is negative the GPs seldom choose triple therapy, and if the result of 
the HP-test is positive they seldom choose only to prescribe Balancid/Zantac. If 
the test is positive, approximately the same percentage of GPs choose the different 
alternatives regardless of whether or not they have the rapid test, showing that 
neither the time aspect nor the fact that the GPs without the rapid test have more 
information in the second consultation influence the GPs’ choice. If the test is 
negative, the table shows that fewer GPs without the test than those with the test 
choose to prescribe Balancid/Zantac, and a much higher number of these choose 
referral. In the second consultation, the GP knows that the patient is not feeling 
better, indicating that the medical actions chosen in the first consultation (often 
only Balancid/Zantac) have not been very successful. Therefore the GPs change 
their strategy, and 81% chose to do further investigations such as a breath test or   16
upper endoscopy. The high number of referrals is consistent with Healy and 
Ryan’s (3) findings that 70% of the GPs will refer a patient to obtain reassurance. 
210 of 425 GPs with HPRT decided to use HPRT but only 100 GPs of 410 GPs 
without HPRT decided to use a serological test. We excluded observations when 
the GP seemed to have misunderstood the question or groups of GPs with deviant 
characteristics. GPs on internship in general practice, age > 67 years, working 
hours > 60 or <10 per week, number of consultations > 160 or < 10 per week, 
waiting time > 26 weeks (concerning referral). Further details on the exclusion of 
the observations are described in appendix B.  
  
The independent variables 
Table 2 gives an overview of our data for the 201 GPs with HPRT and 84 GPs 
without HPRT. These had in common that, in this specific situation, they used a 
HP-test, for example HPRT, or sent a blood test to a “hospital” laboratory  
Table 2 shows that 80.6% of the GPs with HPRT and 76.2% without HPRT are 
male, 77.6% of the GPs with HPRT and 77.4% without HPRT are in group 
practice. 63.2% of the GPs with HPRT and 50% without HPRT are located in an 
urban area, and most of the GPs with HPRT are in private practice.  On average, 
the GP with HPRT has 35 working hours and 89 consultations per week and the 
GP without HPRT has 33 working hours and 75 consultations per week. On 
average, the pre-test-probability is 49.5% for GPs with the test and 48% for GPs 
without the test.  Questions about the importance of HPRT, compared with case 
history and clinical findings, were only asked to GPs with the test. Questions about   17
the importance of HPRT, sick leave, new appointment and post-test-probability 
were related to whether the result of the HP-test was positive or negative.  
For GPs without HPRT we have used information from the questions asked 
regarding the second consultation, and, because of the wording of the 
questionnaire, we believe that the GPs in the second consultation chose fewer 
medical actions, in particular they seldom or never chose “recommend sick leave” 
or “patient initiated new appointment”. In the first consultation the GPs were 
asked to ‘mark’ the chosen medical actions, but in the second consultation the GPs 
had to go back in the questionnaire to find the numbers for each of the chosen 
medical actions.   
We compared the characteristics age, sex, and type of payment in our total 
sample of GPs (both using and not using lab) with the total population of GPs 
(from a register kept by the Norwegian Medical Association). We found that our 
sample had the same mean values regarding age, had a higher percentage of men 
(77% versus 73.6%), and only half the share of the GPs were on fixed salary 
(14.4% versus 28%).  
TABLE 2 
 
We calculated the probability of having an H.pylori-induced ulcer (predictive 
value) by taking into account that a fraction of 15% of the population under 45 
year are healthy carriers of the H.pylori bacterium, and also the sensitivity and 
specificity of both the rapid test and the serological test. We tested whether the 
mean predictive value of the test result was significantly different from the mean 
post-test probability assumed by the GPs, and found that it was only in GPs   18
without the test and with a positive result that the predictive value of the test result 
was not significantly different from the post-test probability assumed by the GPs. 
For GPs with the test, the post-test probability with a positive result was 
significantly higher than the positive predictive value, and significantly lower with 
a negative result than the negative predictive value. For GPs without the test, the 
post-test probability was significantly higher with a negative result than the 
predictive value. The details of the calculations are put in Appendix C. The 
significance of these results will be discussed in section eight.  
 
5. Empirical models 
The theoretical framework is based on discrete choice analyses, see Greene (4).  
  We want to study variables influencing the GPs’ choice of medical actions in 
GPs using a lab in a specific situation. We want to establish models to predict the 
probability of a GP choosing different alternatives. We have three alternatives 
(Balancid/Zantac, referral and triple therapy) that are mutually exclusive, and we 
will use multinomial models. The reference alternative in the model was 
Balancid/Zantac.  
We suppose that the GPs have preferences for different choices, and that these 
preferences can be represented in a utility function. All the GPs have the same 
patient – so the focus here is on the GP’s own objectives and preferences, 
knowledge, experience and uncertainty. The patient here is a paper-patient and the 
patient’s preferences are not known by the GPs.   19
The usefulness of using a laboratory analysis to detect an H.pylori infection will 
depend on the GP’s pre-test probability stated by the GP. The test must also be 
analysed and interpreted correctly. Because some patients are carriers of H-pylori 
without being ill, the use of the test will depend on the GP’s knowledge of 
H.pylori, and on the use of the HP-test. 
 The GPs’ choice setting can be compared with choices between lotteries, 
because of the uncertainty of the initial health status of the patient and of the 
laboratory analysis. The uncertainty of the laboratory analysis occurs because the 
HP-test measures antibodies to the H.pylori bacteria, and not the disease as such, 
and because healthy carriers of the H.pylori bacteria exist. When the GP is 
uncertain about the initial health status, there is also uncertainty about the effect of 
a treatment for a given condition (here an H.pylori infection). The GP may refer 
the patient for a breath test or upper endoscopy to be more certain about the initial 
health status.  
Problems with evaluating the expected utility of the different alternatives are 
that the GP may also have unstable preferences. This means that he may make 
different choices in replications of the same choice setting (bounded rationality). 
The degree of bounded rationality may vary in apparently identical situations 
because the GP is continually being influenced by colleagues, medical journals 
and experience from treating other patients. Further, there will be variation in the 
choices that will not be explained by the variables available to us. Unobservable 
variables for the researcher are the signals from the patient to the GP about 
choosing different medical actions. We have a "paper-patient" and there will   20
therefore be no signals from the patient, except the notion that she was no better in 
the second consultation with GPs without the rapid test.   
Let Uij be the expected utility for GPi, as evaluated by the GPi, with respect to 
the uncertain events mentioned above, given alternatives j = 0,1,2. According to 
the discussion above we assume that the utility Uij is stochastic.  
 
(1a)   Uijt= αij + Xiβj  + εij 
 
where εij is a stochastic term and Xi is a vector of; the characteristics of the GPs, 
the result of the test, the pre-test-probability and the squared pre-test-probability 
for GPs with HPRT. For GPs without HPRT, Xi is a vector of the characteristics of 
the GPs and the post-test-probability and the squared post-test-probability. εijt is 
supposed to account for unobserved variables of the GP that affect his preferences, 
and the fact that the GP may have unstable preferences.  
When t = 1 we study the GPs choice when the test result is negative and when t = 
2 we study the GP’s choice when the test result is positive. Recall that we have 
two observations per GP, one set of medical actions when the HP-test is negative 
and one set of medical actions when the HP-test is positive. There may be 
unobservable heterogeneity of the GPs and correlation between the stochastic 
terms. To take this into account, we use a multinomial logit model with random 
effects, which is a method used for panel data. 
This implies that we can rewrite the model as 
   21
(1b)   Uijt= αj + Xiβj + ε*ijt 
 
where αj is the mean of αij across the population and  
  
  ε*ijt = εijt + αij - αj 
 
which implies that the error term ε* becomes correlated over two periods. We 
assume that the alfas are random effects, thus constant over periods, while the 
epsilons are independent over periods and also independent of the alfas.  
We have included whether the GP recommends sick leave, or how the GP 
follows up the patient as independent variables. But these variables may also 
depend on the medical choice, the endogenous variable, because the GP may 
anticipate that the patient will get strong side effects from triple therapy, which 
may influence the GP to recommend sick leave. This is not a problem as long as 
we are aware of that our model predicts the conditional choice probabilities. Thus 
the probability of choosing triple therapy versus Balancid/Zantac depends on 
whether the GP recommends sick leave, or makes a new appointment, etc. (Ben-
Akiva, Lerman (5)). 
We assume that the GP will choose the alternative with the highest utility 
 
 (2)    Pj(Xi,αi)  = P(Uij >Uik, for all k≠j) = P(αik + Xiβk – αij - Xiβj ≤ εij - 
εik, for all k≠j) 
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where Pj(Xi,αi)  is the probability that the GP will choose the j alternative among 
the three alternatives, conditional on αi, where αi = (αi0, αi1, αi2) 
Let Yij be a random variable that indicates the choice made. Yij=1 if the 
alternative j is chosen by the GPi, and 0 if not.   
McFadden (6) has shown that if (and only if) the three disturbances are 
independent and identically distributed with the extreme value distribution.  
 
(3)  F(εij) = exp(-exp(-εij))  
 
Then   
 
(4)   P(Yij = 1⏐Xi,αi) = P(Xi,αi) = exp(αij + Xiβj)/[∑k=0
2exp(αij + Xiβk)],  
j = 0,1,2 
 
which is to a multinomial logit model. After normalizing such that β0 = 0 where 
alternative zero is the reference, the probabilities are  
 
(5)  P(Yij = 1) = exp(αij + Xiβj)/[1 + ∑k=1
2exp(αij + Xiβk)] for j = 1,2  
 
(6)   P(Yi0 = 1) = 1/[1 + ∑k=1
2exp(αij + Xiβk)],  
 
The log likelihood for random effect is described in NLOGIT versjon 3.0 (7).  
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6. Estimation results   
To estimate the coefficients (the β-vector) in logistic regression we use the 
Maximum Likelihood Method.  
In the tables 3 and 4 we have included the variables that were significant, the 
laboratory related variables and the remuneration variable (private practice). The 
full tables are in appendix D. These tables show the values and the t-ratios on the 
parameters in the models.  
 
The GP’s choice of medical action - GPs with HPRT. 
Here we examine the importance of the characteristics of the GP for the 
probability for choosing different medical actions by estimating a multinomial 
logit model.  
We had 393 observations but these were reduced to 369 observations for the 
standard model, because LIMDEP skip all observations with missing values when 
estimating multinomial logit model. But for the model with random effect we 
needed balanced data and had to exclude GPs who had only chosen one set of 
medical action, and thus had 354 observations.   
We have included results from both the standard multinomial logit, and the 
model with random effect in table 3. By using the LR-test we found that the model 
with random effect is significantly the best model, and we will focus on this model 
when interpreting the table. We see that the parameters in the model with the   24
random effect are a bit less significant and that the significant variables have a 
bigger effect on the probability of the choice.  
TABLE 3 
 
From table 3 we see that the variables having a significant effect on the 
probability of choosing referral versus Balancid/Zantac are: 
-  whether the GP gets a positive or a negative result of HPRT 
-  whether the GP makes a new appointment, 
-  whether the GP asks the patient to make a new appointment if she does not 
recover. 
Table 4 shows that if the HPRT-result is positive the GP chooses referral versus 
Balancid/Zantac 23 times as often as if the HPRT-result is negative. This seems 
reasonable because if the HPRT-test is positive there are reasons for further 
investigations to find out whether this patient has a HP-infection. 
GPs who make a new appointment or/and ask the patient to make a new 
appointment if she does not recover, choose referral vs. Balancid/Zantac 0.12 and 
0.07 times as often as GPs who do not arrange for a follow up of the patients. This 
may be because only prescribing symptomatic treatment demands more follow up 
from the GP (ref. section three).  
  From table 3 we see that the variables with a significant effect on the probability 
of choosing the triple therapy versus Balancid/Zantac are: 
-  whether the GP gets a positive or a negative result of HPRT, 
-  whether the GP gives the importance of HPRT a high point 
-  whether the GP recommends sick leave.   25
The results show that the lab result in particular has a major influence on the 
probability of the GP choosing triple therapy versus Balancid/Zantac. If the 
HPRT-result is positive, the GP chooses triple therapy versus Balancid/Zantac 966 
times as often as if the HPRT-result was negative. If the GP increase the 
importance of the HPRT-test by one point, the GP will choose triple therapy 
versus Balancid/Zantac 1.62 times more often as before. 
GPs who recommend sick leave choose triple therapy 6.38 times more often 
than Balancid/Zantac, compared with GPs who do not recommend sick leave. 
Recall here from section five that we have conditional choice probabilities, the 
probability of a GP choosing triple therapy vs. Balancid/Zantac is given whether 
they have recommend sick leave or not. 
 
The GP’s choice of medical actions - GPs without HPRT.  
Here we examine the importance of variables on the probability of choosing 
different medical actions in the second consultation (when the test result was 
available) by estimating a multinomial logit model.  
In this section we use the post-test-probability instead of the pre-test-probability 
and the result of the HP-analysis, because, as table 3 showed, all the GPs choosing 
triple therapy had a positive lab result and we had too little variation in the data to 
be able to use this variable. 
We had 162 observations but these were reduced to 156 in the standard model, 
because LIMDEP skips all observations with missing values when estimating 
multinomial logit model. But in the model with random effect we had to have   26
balanced data and had to exclude GPs who had only chosen one set of medical 
action, leaving us with 139 observations.      
TABLE 4 
 
In table 4 we have included results from both the standard multinomial logit, and 
the model with random effect. By using the LR-test we found that the model with 
random effect was not a significantly better model than the standard model.  
Table 4 shows that the post-test-probability and the location of the practice 
(semi-urban vs. uban) are the only variables that have a significant effect. We also 
see that the post-test probability is non-linear. From the table we see that the odds 
ratio for choosing referral vs. Balancid/Zantac is ca.1.33, and that the odds ratio 
for choosing triple therapy vs. Balancid/Zantac is ca.1.48. Thus if the GP has a 
post-test-probability of 50%, the GP will choose referral 66.5 times as often as 
Balancid/Zantac, and triple therapy 74 times as often as Balancid/Zantac.  
If the general practice is located in the urban area vs. a semi-urban area it is 8.33 
times as often that the GP choose referral vs. general practice located in the semi-
urban area.  
It may seem strange that the choice of medical actions in the second 
consultation does not depend on the first consultation, but this may be because the 
24 GPs who chose referral in the first consultation also chose referral in the second 
consultation, because neither upper endoscopy nor the breath test had been carried 
out when the patient came to the second consultation. 
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7. The effect of changes in significant variables  
In this section we only use the results from the standard multinomial model for 
GPs with HPRT. 
Calculations in Appendix E show that the probability that “our” GP with HPRT 
chooses referral vs. Balancid/Zantac is 95%, and the probability of choosing triple 
therapy vs. Balancid/Zantac is 85.9%. The marginal effects on the probability are 
listed in table 5.  
 
TABLE 5 
Table 5 shows that the HP-test has the greatest effect on the GP’s decision of 
choosing medical action. Our GP has a probability of 90.5% of choosing referral, 
and if the HP-test is negative for an identical GP, the probability will decrease by 
54.5%.  
Our GP does not ask the patient to make a new appointment. In the third line in 
table 5 it is shown that an identical GP who asks the patient to make a new 
appointment will decrease the probability by 37.9% compared with our GP, thus 
the probability that this GP chooses referral versus Balancid/Zantac is 53.3%.  
Our GP has a probability of 85.9% of choosing triple therapy versus 
Balancid/Zantac, and if the HP-test is negative for an identical GP, the probability 
will decrease by 84.3%. Thus the probability that this GP will choose triple 
therapy versus Balancid/Zantac is 0.04%. Our GP does not recommend sick leave. 
Table 5 shows that an identical GP who recommends sick leave will have a 
probability of 96.3 of choosing triple therapy versus Balancid/Zantac.    28
8. Concluding remarks  
We have developed a method for studying the effect of a specific laboratory 
analysis on choosing medical actions. By using discrete choice analysis and 
multinomial logit models, we have seen that the result of the HP-analysis has a 
significant influence on a GP’s choice of medical actions. We plan similar future 
studies of different types of laboratory analyses before we can draw general 
conclusions. However, it is reasonable to assume that we will find similar results 
in clinical situations where other tests are rarely needed. It is also reasonable to 
assume that the GPs in Norway are representative for the practice in other western 
countries 
We will now discuss some objections to the methods we have used. 
  Our data is based on a questionnaire where the GP is given enough information 
to establish a preliminary diagnosis. In writing the clinical vignette it was 
important to describe a realistic situation to get valid results. But in a questionnaire 
we loose the interaction between the patient and the GP. The patient could have 
wanted to have the laboratory test taken, but the Helicobacter Pylori analysis is not 
very well known in Norway, so this is not very likely.  
In the literature there have been discussions about the validity of written case 
scenarios in medical decision-making. One might say that by using a clinical 
vignette we measure competence (what a physician is capable of doing), and not 
performance (what a physician actually does in his day-to-day practice). 
Kuyvenhoven and co-workers (8) conclude that written simulations give a realistic 
impression of a GP’s diagnostic and therapeutic approach to patients with vague   29
symptoms like those in our clinical vignette. By use of clinical scenarios, 
Redelmeier and Tversky (9) noted that physicians are more likely to request 
ineffective care when presented with a named patient than when a general question 
about the strategy is asked. In a review of 74 published studies using written 
simulations, the validity issue was addressed in only 11 studies, and the 
conclusions were conflicting (Jones TV et al (10)). Sandvik H (11) studied the 
validity of responses to patient vignettes in a situation based on the management of 
female urinary incontinence, and found that when cueing items were provided the 
physician claimed more actions with vignettes than were actually performed. In 
our situation this means that waiting and travelling time for an upper endoscopy 
will probably have a significant effect in a real consultation compared with our 
findings, because the GP considers the patients convenience more in actual 
encounters with the patient, and this will make it easier to start treatment versus 
referral. 
Peabody et al (12) have validated clinical vignettes as a method for measuring the 
competence of physicians and the quality of their actual practice, and conclude 
that the quality of care can be measured by using clinical vignettes. 
Bias is more likely if the respondents feel obliged to display some kind of 
expected behaviour or/and if the written scenario differs from a typical situation. 
Our case history depicts a real patient with some minor modifications, in order to 
make the situation as realistic as possible.  
NOKLUS mails questionnaires 2-3 times a year. The GPs receive feedback 
reports with their answers compared with the results of other GPs, and with 
clinical guidelines about the use of the laboratory analysis in question. It is   30
possible that the GPs who respond make an extra effort to study H-pylori in order 
to try to score better than most of their colleagues. If so, their answers to the 
questionnaire will reflect their level of competence at the ‘later consultations’ and 
not the consultations they had before receiving the questionnaire. We also believe 
that we have a selection problem because the GPs responding on the questionnaire 
are probably more eager than those not responding.  
Recall that we assumed that the GPs were motivated by the patients’ interests 
guided by the best clinical evidence available. This is not an uncontroversial 
assumption. In the literature, various models of GP behaviour are suggested, as 
described by Scott (13). A basic income-leisure framework is common to many 
models. In these, the GPs are modelled as self-employed individuals who supply 
their own labour and have their own objectives regarding leisure and the 
consumption of other goods. Other models have included “inducement” in the 
utility function to represent the disutility from physician-induced demand (PID). 
PID exists when the GP influences a patient’s demand for care against the GP’s 
interpretation of the best interest of the patient (McGuire 14). The majority of 
models have examined treatment decisions as the main decision variable, as our 
model does.  
 The only way a GP can increase his income from private practice in our 
setting is to influence the number of consultations by influencing the number of 
follow-up visits. The motivation for influencing the number of consultations in 
GPs with private practice depends on whether the GP feels that he has enough 
patients. Figure 2 shows how the GP can influence the number of consultations.   31
If the GP feels he has too few patients, there is an economic incentive to initiate 
follow-up visits. If the GP feels he has enough patients he may be concerned about 
the availability of services to the other patients, for ethical reasons and 
independently of the remuneration system. He may therefore ration his services or 
induce negatively, as explained in McGuire (14). In our case, the GP can influence 
utilization in different ways. If the GP feels that he has enough patients, the GP 
may ask the hospital to start treatment if the test result is positive and examination 
at the hospital indicates that the patient has an H.pylori infection. If the GP 
chooses to give the triple therapy, the patient will only return if she does not 
improve. Thus both relevant alternatives enable the GP to avoid a new 
consultation if the patient has an H.pylori infection. If the patient does not have the 
infection and does not recover, she will return to the GP with both alternatives  
FIGURE 2 
 
If the GP lacks patients he may tend to choose to refer the patient to the hospital 
and ask the hospital not to start treatment after the examination, and make a new 
appointment, independently of the alternative chosen. But the decision whether or 
not to start treatment is usually done at the hospital. This was taken care of by 
including follow-up as an independent variable.  
If the test is negative and the GP lacks patients, he may only prescribe 
Balancid/Zantac and make a new appointment. If the GP has enough patients he 
may prescribe Balancid/Zantac without making a new appointment and/or inform 
the patient that the symptoms are temporary and not dangerous, or refer the patient 
without a follow-up to reassure the patient.    32
However, we do not know the actual number of patients compared with the 
preferred number of patients for each GP and are not able to test for physician-
induced demand. 
The answer to the question "Need for information about the use of the test" is 
the GP’s own evaluation. Regarding the question about the “most important 
information sources for HPRT", it is possible that the GPs answer what they 
believe would be accepted by their colleagues. 
Recall that by estimating the predictive value and comparing with the post-test-
probability assumed by the GPs, we found that it was only GPs without the 
H.pylori test and with a positive result that had managed to estimate the post-test-
probability correctly, based on the pre-test-probability and the result of the test. 
We also found that GPs with HPRT overestimated the value of the test and this 
agrees with results from Steurer et al. (15), who found that doctors tend to 
overestimate information derived from diagnostic tests and underestimate 
information from a patient’s clinical history. Steurer et al. have studied the extent 
to which different forms of summarising diagnostic test information influence 
general practitioners’ ability to estimate disease probabilities. They found that 
many doctors confuse the sensitivity of clinical tests and their positive predictive 
value. The consequence of overestimating results of the H.pylori analysis is that if 
the test result is positive, more patients will be given the triple therapy than 
necessary, which may increase resistance to antibiotics.  
We conclude that, since the result of laboratory tests in our study affect the 
choice of medical action, the quality of the laboratory test is likely to have an 
effect on patients’ health and social costs. Hence, institutions for quality   33
monitoring and improvement are important ingredients of health care reform. Such 
institutions should balance cost and the benefits of quality improving measures, 
and will be the focus of closer study in our future research. We want to develop a 
method that can be used to evaluate the economical consequences of good quality 
of a laboratory analysis through a cost-benefit analysis.   34
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THE NORWEGIAN QUALITY IMPROVEMENT OF 
LABORATORY SERVICES IN PRIMARY CARE  
 
NOKLUS is financed by Quality Assurance Fund III, which was established by The 
Norwegian Medical Association, The Norwegian Association of Local and 
Regional Authorities, and The Ministry of Health and Social Affairs. 
 
 
Dear General practitioner   
 
Many so-called rapid tests have been developed for use in the doctor’s surgery. One of the most recent 
on the market is the Helicobacter pylori test. However, we know little about how much 
importance is attached to this test in clinical practice and the consequences of the result.  
 
We have therefore constructed a short case history, which is presented below. The case history is 
modelled on a real patient, and all the relevant information is included. However, as in most case 
records, it is not possible to present all the details. We ask you to read the case history carefully, and to 
cross off the proposed measure(s) that you would initiate if you were treating this patient in your 
surgery today.  
 
The results will be used in the preparation of guidelines for using this test. The objective of this 
questionnaire is slightly different from the casuistic material that you otherwise receive from 
NOKLUS, and control material is therefore not enclosed.  
 
We hope that you will set aside a few minutes to fill in this form. It is only labelled with a practice 
number and will be treated confidentially. You will be sent a feedback showing the distribution of 
answers and including professional information before the end of June.  
 




Atle Klovning     Sverre Sandberg  Geir  Thue    Siri  Fauli 
Research Fellow       Leader, NOKLUS           GP/Specialist NOKLUS   Master degree student 
 


















•  How likely do you think it is that Mrs Hansen’s symptoms are caused by an H. pylori infection:  
_______ % 
(0% - absolutely certain that H. pylori is not the cause, 100% - absolutely certain that H. pylori is 
the cause) 
 
•  Would you have used the H. pylori rapid test here?  θ1      no   (answer sections A and C) 
(put a cross to show your choice)    θ2      yes (answer sections B1, B2 and C) 
Anette Hansen  
is 31 years old and works for 5 hours a day in the afternoon/evening as a cleaner. Married, usually 
happy at home, two children aged 11 and 6 years.  
 
During the past month she has had epigastric pain with a feeling of hunger, and some relief on eating. 
Experiences that the pain increases when she under stress. Slightly loose and irregular defecation at 
times.  
 
She had a similar episode just under a year ago, and then recovered rapidly with Zantac 150 mg x 2, 
which she took for just over a week during her summer holidays. No other measures were taken at 
this consultation. She smokes 10 cigarettes a day, 2-3 cups of coffee, consumes little alcohol. No 
medication.   
 
When you examine her this Tuesday she is slightly tender over her epigastrium, no other findings. 
  
She should be at work later today.  Appendix A 
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A You  choose  not to carry out the Helicobacter pylori rapid test 
 
 
•  Draw a circle round the number indicating the measure(s) that you will initiate at today’s 
consultation: 
 
1  -advice on life-style 
2  - advise to take Balancid or similar 
3  - trial treatment with Zantac or similar 
4  - trial treatment with one of the triple regimens against H. pylori 
5  - referral for a breath test to demonstrate H. pylori 
6  - referral to gastroscopy  
7  - suggest sick leave for the patient this Tuesday  
For how long? …… days  
8  - make a follow-up appointment for the patient  
9  - ask the patient to renew contact if she does not recover 
 
Other measures if relevant (please specify): 
 
 
•  Mrs Hansen returns after 2 weeks.  
 
She is no better.  
Neither gastroscopy nor a breath test (if relevant) has been carried out. 
 
Please answer one of the two alternatives below,  
and specify the measures you will initiate using the numbers given above, e.g. 6 if you now refer to gastroscopy , 7 
for (extended) sick leave, etc.  
 
If relevant, you can enter other measures at the bottom of this page  
 
 




II.  You choose to carry out an H. pylori rapid test and receive the result during the consultation (please answer both a 
and b) 
 
a.  the result is negative.  
How likely do you now think it is that Mrs Hansen’s symptoms are caused by an H. pylori infection? ____% 
 
You initiate the following measures (specify using numbers as above): ___________________________ 
   
b.  the result is positive  
How likely do you now think it is that Mrs Hansen’s symptoms are caused by an H. pylori-infection? ____% 
 
You initiate the following measures (specify using numbers as above): ___________________________ 
 




Proceed to section C Appendix A 
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B  You choose to carry out an H. pylori rapid test (please answer both B1 and B2) 
 
 
B1  The result of the H. pylori rapid test is negative 
 
•  How likely do you now think it is that Mrs Hansen’s symptoms are caused by an H. pylori infection? _______ % 
 
 
•  How much importance do you attach to the case history and clinical examination of Mrs Hansen and the result of the 
H. pylori rapid test in relation to each other?  
You have 10 points to allot (give most points to the factor that you consider most important): 
 
case history ______  examination ______  test ______ (in total: 10 points) 
 
 
•  Draw a circle round the number specifying the measure(s) that you will initiate at today’s consultation: 
 
1  - advice on life-style 
2  - advise to take Balancid or similar 
3  - trial treatment with Zantac or similar 
4  - trial treatment with one of the triple regimens against H. pylori 
5  - referral for a breath test to demonstrate H. pylori 
6  - referral to gastroscopy  
7  - suggest sick leave for the patient this Tuesday  
For how long? …… days  
8  - make a follow-up appointment for the patient  
9  - ask the patient to renew contact if she does not recover 
 
Other measures if relevant (please specify): 
 
 
•  Mrs Hansen returns after 2 weeks.  
 
She is no better.  
Neither gastroscopy nor a breath test (if relevant) has been carried out. 
 
Specify the measures that you will now initiate using numbers, e.g. 6 if you now refer for gastroscopy, 7 for 
(extended) sick leave etc. ________________ 
 
Other measures if relevant (please specify): 
 
 
Proceed to section B2 Appendix A 
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B2  The result of the H. pylori rapid test is positive  
 
 
•  How likely do you now think it is that Mrs Hansen’s symptoms are caused by an H. pylori infection? _______ % 
 
 
•  How much importance do you attach to the case history and clinical examination of Mrs Hansen and the result of the 
H. pylori rapid test in relation to each other?  
You have 10 points to allot (give most points to the factor that you consider most important): 
 
case history ______  examination ______  test ______ (in total: 10 points) 
 
 
•  Draw a circle round the number specifying the measure(s) that you will initiate at today’s consultation: 
 
1  -advice on life-style 
2  - advise to take Balancid or similar 
3  - trial treatment with Zantac or similar 
4  - trial treatment with one of the triple regimens against H. pylori 
5  - referral for a breath test to demonstrate H. pylori 
6  - referral to gastroscopy  
7  - suggest sick leave for the patient this Tuesday  
For how long? …… days  
8  - make a follow-up appointment for the patient  
9  - ask the patient to renew contact if she does not recover 
 
Other measures if relevant (please specify): 
 
 
•  Mrs Hansen returns after 2 weeks.  
 
She is no better.  
Neither gastroscopy nor a breath test (if relevant) has been carried out. 
 
Specify the measures that you will now initiate using numbers, e.g. 6 if you now refer for gastroscopy, 7 for 
(extended) sick leave etc. ________________ 
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C Background  information 
 
 
•  The travelling time (one way) for a patient to carry out gastroscopy is generally   ________hours 
 
•  The waiting period for a gastroscopy where you usually refer patients is generally   ________weeks 
 
•  The travelling time (one way) for a patient to carry out a breath test is generally  ________hours 
 
•  The waiting period for a breath test is generally          ________weeks 
θ       do not have this possibility 
 
•  Do you sometimes refer patients to a private clinic where they have to pay more in order to be able to carry out 
gastroscopy?   
θ1   y ye es s        
θ2      no         
θ3   d do o   n no ot t   h ha av ve e   t th hi is s   p po os ss si ib bi il li it ty y 
 
•  To what extent do you feel that you need information on the use of the H. pylori rapid test? 
θ1    no need 
θ2    slight need of information 
θ3      s so om me e   n ne ee ed d  
θ4      a a   g gr re ea at t   n ne ee ed d   o of f   i in nf fo or rm ma at ti io on n 
 
•  Which have  been your two most important sources of information on the use of the H. pylori rapid test? 
θ1      i information from the dealer (visit by representative, displays at courses, material sent by post) 
θ2      The Journal of The Norwegian Medical Association 
θ3      course 
θ4      j jo ou ur rn na al ls s   p pu ub bl li is sh he ed d   b by y   t th he e   p ph ha ar rm ma ac ce eu ut ti ic ca al l   i in nd du us st tr ry y, e.g. Legemidler og Samfunn, Therapia Medica 
θ5      o ot th he er r, specify_____________________________________________________ 
 
•  Your year of birth:  ________ 
•  Gender:     ________ (M/F) 
•  Your initials:   ________  (in capital letters and clear, to facilitate the feedback)  
 (continued on next page) Appendix A 
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•  You work in      θ1      a a   group practice   
θ2    a single doctor practice 
 
 
•  The practice is located in      θ1    a town/densely populated area with more than 15 000 inhabitants 
    θ2      a a   d de en ns se el ly y   p po op pu ul la at te ed d   a ar re ea a   w wi it th h   b be et tw we ee en n 5000 and 15 000 inhabitants 
θ3    a rural district – less than 5000 inhabitants in the largest densely populated area 
in the area covered  by the practice 
       
 
•  Working hours in curative practice per week are about ________hours 
 
•  Number of consultations in the course of a normal working week is about ________ (number) 
 
•  In your practice do you have  θ1      r re ef fu un nd d   f fr ro om m   t th he e   N Na at ti io on na al l   H He ea al lt th h   I In ns su ur ra an nc ce e, ,   a an nd d   a an n   operating subsidy   
    θ2    a fixed salary 
    θ3      fastlegeordning (system providing each citizen with permanent doctor) 
    θ4    only refund from National Health Insurance, no operating subsidy 
    θ5    a practice with no refund or operating subsidy 
 
•  Are you a specialist in general medicine?   
θ1    no     
θ2      yes 
θ3    no, I am doing my pre-registration service (internship in GP) 






Thank you for your participation! 
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THE NORWEGIAN QUALITY IMPROVEMENT OF 
LABORATORY SERVICES IN PRIMARY CARE  
 
NOKLUS is financed by Quality Assurance Fund III, which was established by The 
Norwegian Medical Association, The Norwegian Association of Local and 
Regional Authorities, and The Ministry of Health and Social Affairs. 
 
 
Dear General practitioner   
 
The guidelines for the use of Helicobacter pylori serology in the investigation of dyspepsia are 
not clear, both as regards submitted blood samples and use of rapid tests. We know little about how 
much importance is attached to the serology results in clinical practice and the consequences of the 
result.  
 
We have therefore constructed a short case history, which is presented below. The case history is 
modelled on a real patient, and all the relevant information is included. However, as in most case 
records, it is not possible to present all the details. We ask you to read the case history carefully, and to 
cross off the proposed measure(s) that you would initiate if you were treating this patient in your 
surgery today.  
 
The results will be used in the preparation of guidelines for using H. pylori serology. The objective of 
this questionnaire is slightly different from the casuistic material that you otherwise receive from 
NOKLUS, and it is therefore also sent to practices that do not have this rapid test.  
 
We hope that you will set aside a few minutes to fill in this form. It is only labelled with a practice 
number and will be treated confidentially. You will be sent a feedback showing the distribution of 
answers and including professional information before the end of June.  
 





Atle Klovning     Sverre Sandberg  Geir  Thue    Siri  Fauli 
Research Fellow       Leader, NOKLUS           GP/Specialist NOKLUS   Master degree student 
 


















•  How likely do you think it is that Mrs Hansen’s symptoms are caused by an H. pylori infection:  
_______ % 




Anette Hansen  
is 31 years old and works for 5 hours a day in the afternoon/evening as a cleaner. Married, usually 
happy at home, two children aged 11 and 6 years.  
 
During the past month she has had epigastric pain with a feeling of hunger, and some relief on eating. 
Experiences that the pain increases when she under stress. Slightly loose and irregular defecation at 
times.  
 
She had a similar episode just under a year ago, and then recovered rapidly with Zantac 150 mg x 2, 
which she took for just over a week during her summer holidays. No other measures were taken at 
this consultation. She smokes 10 cigarettes a day, 2-3 cups of coffee, consumes little alcohol. No 
medication.   
 
When you examine her this Tuesday she is slightly tender over her epigastrium, no other findings. 
  
She should be at work later today.  Appendix A 
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•  Draw a circle round the number indicating the measure(s) that you will initiate at today’s 
consultation: 
 
1    advice on life-style 
2    advise to take Balancid or similar 
3     trial treatment with Zantac or similar 
4  trial treatment with one of the triple regimens against H. pylori 
5  send a blood sample for serological demonstration of H. pylori 
6  referral for a breath test to demonstrate H. pylori 
7  referral to gastroscopy 
8  suggest sick leave for the patient this Tuesday  
       For how long? …… days  
9    make a follow-up appointment for the patient  
10  ask the patient to renew contact if she does not recover 
 
Other measures if relevant (please specify): 
 
 
•  Mrs Hansen returns after 2 weeks.  
 
She is no better.  
Neither gastroscopy nor a breath test (if relevant) has been carried out. 
 
Please answer one of the two alternatives below,  
and specify the measures you will initiate using the numbers given above, e.g. 7 if you now refer to gastroscopy , 8 
for (extended) sick leave, etc.  
If relevant, you can enter other measures at the bottom of this page  
 
 
II.  You did not order H. pylori serology at the previous consultation. 
You now initiate the following measures (specify using numbers as above):  ______________ 
 
 
II.    You ordered H. pylori serology at the previous consultation (please answer both a and b) 
 
c.  the H. pylori serology result is negative.  
How likely do you now think it is that Mrs Hansen’s symptoms are caused by an H. pylori infection? ____% 
 
You initiate the following measures (specify using numbers as above): ___________________________ 
   
d.  the H. pylori serology result is positive  
How likely do you now think it is that Mrs Hansen’s symptoms are caused by an H. pylori-infection? ____% 
 
You initiate the following measures (specify using numbers as above): ___________________________ 
 
Other measures if relevant (please specify): Appendix A 
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C Background  information 
 
 
•  The travelling time (one way) for a patient to carry out gastroscopy is generally   ________hours 
 
•  The waiting period for a gastroscopy where you usually refer patients is generally   ________weeks 
 
•  The travelling time (one way) for a patient to carry out a breath test is generally  ________hours 
 
•  The waiting period for a breath test is generally           ________weeks 
θ       do not have this possibility 
 
•  Do you sometimes refer patients to a private clinic where they have to pay more in order to be able to carry out 
gastroscopy?   
θ1   y ye es s        
θ2      no         
θ3   d do o   n no ot t   h ha av ve e   t th hi is s   p po os ss si ib bi il li it ty y 
 
•  To what extent do you feel that you need information on the use of the H. pylori rapid test? 
θ1    no need 
θ2    slight need of information 
θ3      s so om me e   n ne ee ed d  
θ4      a a   g gr re ea at t   n ne ee ed d   o of f   i in nf fo or rm ma at ti io on n 
 
•  Which have been your two most important sources of information on the use of the H. pylori rapid test? 
θ1      i information from the dealer (visit by representative, displays at courses, material sent by post) 
θ2      The Journal of The Norwegian Medical Association 
θ3      course 
θ4      j jo ou ur rn na al ls s   p pu ub bl li is sh he ed d   b by y   t th he e   p ph ha ar rm ma ac ce eu ut ti ic ca al l   i in nd du us st tr ry y, e.g. Legemidler og Samfunn, Therapia Medica 
θ5      o ot th he er r, specify_____________________________________________________ 
 
•  Your year of birth:  ________ 
•  Gender:     ________ (M/F) 
•  Your initials:   ________  (in capital letters and clear, to facilitate the feedback)  
 (continued on next page) Appendix A 
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•  You work in      θ1      a a   group practice   
θ2    a single doctor practice 
 
 
•  The practice is located in      θ1    a town/densely populated area with more than 15 000 inhabitants 
    θ2      a a   d de en ns se el ly y   p po op pu ul la at te ed d   a ar re ea a   w wi it th h   b be et tw we ee en n 5000 and 15 000 inhabitants 
θ3    a rural district – less than 5000 inhabitants in the largest densely populated area 
in the area covered  by the practice 
       
 
•  Working hours in curative practice per week are about ________hours 
 
•  Number of consultations in the course of a normal working week is about ________ (number) 
 
•  In your practice do you have  θ1      r re ef fu un nd d   f fr ro om m   t th he e   N Na at ti io on na al l   H He ea al lt th h   I In ns su ur ra an nc ce e, ,   a an nd d   a an n   operating subsidy   
    θ2    a fixed salary 
    θ3      fastlegeordning (system providing each citizen with permanent doctor) 
    θ4    only refund from National Health Insurance, no operating subsidy 
    θ5    a practice with no refund or operating subsidy 
 
•  Are you a specialist in general medicine?   
θ1    no     
θ2      yes 
θ3    no, I am doing my pre-registration service (internship in GP) 






Thank you for your participation! 
A prepaid envelope for your reply is enclosed 
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Appendix B Exclusion and grouping of the observations 
After exclusion we had 201 GPs with HPRT and 84 GPs without HPRT who 
requested this analysis (9 and 16 doctors excluded respectively). We had two sets 
of observations per GP (depending on whether the test result was positive or 
negative); 402 observations with HPRT and 168 observations without HPRT. 
Because of missing observations and 4 GPs who chose no medical action 
(regarded as an incomplete answer), we had 393 observations for GPs with HPRT. 
For GPs without the test there were 13 observations where the GPs who had 
chosen no medical action in the second consultation, had chosen Balancid/Zantac 
(6) and referral (7) in the first consultation. The six observations where no medical 
actions were chosen in the second consultation, and only Balancid/Zantac in the 
first consultation were regarded as missing observations and excluded. We coded 
the 7 observations with referral in the second consultation in the same way as in 
the first consultation. Hence we had 162 observations.   50
Appendix C Testing of the predictive value versus the post-test-
probability 
By using Bayes law we calculated in LIMDEP the probability of having an 
H.pylori-infection (predictive value) by taking into account that 15% of the 
population under 45 years are healthy carriers of the H.pylori bacterium and the 
sensitivity and the specificity of the rapid test or the serological test.  
We tested whether the predictive value of the test result was significantly different 
from the post-test probability assumed by the GPs. The details are shown below.  
 
Calculation of the predictive value vs. the post-test-probability 
We are going to calculate the effect of the lab result when 15% of the population is 
healthy carriers of the H pylori bacteria. Table C.1 shows the results of the 
calculations. The pre-test-value in our example is 0.2, thus the GP assume that 200 
among 1000 similar patients are infected and 800 are not infected. 
We show here the calculations for the predictive value of the HPRT. Similar 
calculations are done for the serological test. From ch.2 we know that the 
serological testing is more accurate than HPRT because it has higher sensitivity 
(95% versus 85%) and specificity (95% versus 80%) for detection of H pylori. 
The number of persons having the bacteria without being infected is 120 
(800*15%) persons, and 680 persons (800-120) don’t have the bacteria. It is not 
possible to be infected without having the bacteria. 
Table C.1 
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Possible outcomes where the HPRT is positive  
1. Number of persons having the bacteria and being infected. 
Total number of persons giving the bacteria and being infected* sensitivity 
=Pre-test-probability*1000* sensitivity= 200*0.85=170 persons 
 
2. Number of persons having the bacteria and not being infected. 
Total number of persons having the bacteria and not being infected *sensitivity 
=120*0.85 = 102 persons 
 
3. Number of persons without the bacteria and not being infected. 
Total number of persons without the bacteria and not being infected*(1-
specificity) 
= 680*0.2 = 136 persons  
 
Calculation of the positive predictive value; 
Number with the bacteria being infected/ all possible outcomes= 
170/(170+102+136) = 0.4167 
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Possible outcomes when the HPRT is negative  
1. Number of persons having the bacteria and being infected 
Total number of persons having the bacteria and being infected 
= Pre-test-probability*1000*15 (1- sensitivity)  =200*15  
= 30 persons 
 
2. Number of persons having the bacteria and not being infected 
= Total number of persons having the bacteria and not being infected  
= 120*15% (1-sensitivity) = 18 persons 
 
3. Number of persons without the bacteria and not being infected  




Calculation of the negative predictive value; 
Number with the bacteria not being infected/ all possible outcomes  
= 18+544/(30+18+544)=0.949 
 
For GPs having HPRT 
We study the mean from the two samples where  
μ1 = “pospred” in tables below = mean of the calculated positive? predictive value   53
μ2 =“postsan” in tables below = mean of the post-test-probability given by the GPs 
 
We find the T-value by using the formula 
T= μ1 - μ2 /√(σ1
2/n1 + σ2
2/n2) 
Where σi = the standard deviation of sample i, i  = 1,2 
We compare the T-value with the critical t-value, to study if the means are 
significantly different 
Our zero hypothesis is H0 = μ1 - μ2 = 0. If |T|| ≥ t0.05=1.96, we reject H0 , i.e. we 
reject that the means are equal. 
The tables C.2 and C.3 shows the mean, std.deviation, minimum, maximum and 
number of rows (3 lines per observation because each GP choose between three 
alternatives).  
When the HPRT is positive: 
T=68.04-76.31/√(0.62 + 0.47) = - 8.27/1.04= - 7.95 
The t-value is above the critical t-value on 1.96 and this means we reject H0 
 
When the HPRT is negative 
T=20.38-15.6/√(0.33 + 0.35) = 4.8/0.82 = 5.85 
The t-value is above the critical t-value on 1.96 and this means that we reject H0 
TABLE C.2When the serologic test is positive: 
T=76.54-79.57/√(1.694 + 1.466) = - 3.03/1.77= - 1.71 
The t-value is not above the critical t-value on 1.96 and this means that we cannot 
reject H0 saying that the two means are equal.   54
TABLE C.2 
For GPs without HPRT 
TABLE C.3 
When the serologic test is negative: 
T=9.13-16.4/√(1.07 + 1.81) = - 7.3/1.69 = - 4.3 
The t-value is above the critical t-value on 1.96 and this means that we reject H0 
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Appendix D  - Full models  
Table D.1 and table D.2 include all the estimation results of full models 
TABLE D.1 
 
TABLE D.2   56
Appendix E The effect of changes in significant variables 
We have non-linear data, and cannot interpret the coefficients as we do in 
ordinary linear regression. Let P1(Xi) be the probability of GPi choosing alternative 
1. If we study a change in  
P1(Xi) as a result of a change in one of the continuous variables (variable nr. k), 
we will get;  
 
(10)   ∂ P1(Xi)/∂Xik = (1-P1(Xi))P1(Xi)βk.  
 
For continuous variables this means that the effect of the variable will depend on 
the level of the variable, for example if the GP is 30 or 40 years old. 
  Many of our explanatory variables are binary, and here they have the value 1 or 
0, depending on the characteristics of the GP. If we want to study the effect of a 
change in a binary variable, we do this by calculating the difference: 
 
(11)   P1(X*i) - P1(Xi) = 1/[1 + exp(-X*iβ)] - 1/[1 + exp(-Xiβ)] 
 
where X*i is the vector of characteristics after the change, and Xi is the vector of 
variables before the change.  
We want to study the magnitude of the effect of significant variables on the 
probability of choosing referral vs. Balancid/Zantac and of choosing triple therapy 
vs. Balancid/Zantac. As an example, a GP with the following characteristics (after 
this named “our GP”):   57
-  male, 45 years old 
-  needs information on the use of HPRT 
-  the HP-analysis is positive 
-  does not use supplier's information only   
-  works 35 hours with 90 consultations per week in a group practice 
-  is paid fee-for-service  
-  lives in an urban area 
-  estimates a pre-test-probability of 30% and with a positive H.pylori analysis 
estimates a post-test-probability of 50% that the dyspepsia is due to a H pylori 
infection  
-  does not have a specialist licence in general practice/family medicine 
-  gives the relative importance of the HPRT-test 3 points on a scale from 1 to 10 
-  does not recommend sick leave for Mrs Hansen 
-  does not schedule a follow-up appointment 
-  has one hour’s travelling time for upper endoscopy, and 4 weeks waiting time 
-  chooses Zantac/Balancid in the first consultation (in GPs without HPRT) 
We study the effect of significant variables and calculate the probability of 
choosing triple therapy or referral in GPi, by putting in the values of the 
coefficients and the characteristics in the formula for the probability of choosing 
triple therapy or referral vs. Balancid/Zantac.   
When we study the effect of a change in a characteristic of the GP, we do similar 
calculations and change one characteristic leaving the others unchanged. We name 
the new probability P1(X*) as in (11). 
GPs with HPRT    58
In estimating the probability we use results from the standard model in table 6.1 
and the characteristics on the GP mentioned in section 7. 
 
Calculation of the probability of choosing Referral vs. Balancid/Zantac 





-(1.630 + 2.847*1-0.088*3 - 0.030*30 + 0.0004*900 + 0 + 0.003*45 - 0.125 – 0.422 + 0  - 0.351+ 0 – 1.097 –
0.013*1 + 0.008*4+ 0.009*35+0.002*90 + 0 -  0 + 0) = 
1/1+e
(1.630 + 2.847 - 0.264 - 0.90 + 0.36 + 0.135 - 0.125 – 0.422  - 0.351 – 1.097 –0.013 – 0.032+ 0.315+0.18) 
=1/1+e
-(2.263)=1/1+0.104= 0.905, thus there is a 90.5% probability that this GP will 
choose Referral vs. Balancid/Zantac and P1(Xi) = 90.5%. 
 
Effect of the result of HPRT 
When we study the effect of a GP receiving a negative vs. a positive 
laboratoryresult, other variables remaining unchanged, we get 
1/1+e
-(2.263-2.847)=1/1+1.793= 0.358, thus there is a 35.8% probability that this GP 
will choose Referral vs. Balancid/Zantac and P1(Xi*) = 35.8%. 
The effect of HPRT is a decrease in the probability by  
dP1(Xi)/dXif
 =P1(Xi*)-P1(Xi)=  54.5%. 
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Effect of the GPs follow-up   
A) We study the effect of a GP making a new appointment vs. not making a new 
appointment, other variables remaining unchanged and get 
1/1+e
-(2.263-1.744)=1/1+0.595 = 0.627, thus there is a 62.7% probability that this GP 
will choose Referral vs. Balancid/Zantac and P1(Xi*) =62.7%. 
The effect of the new appointment is a decrease in the probability by  
dP1(Xi)/dXinf
 =P1(X*i)-P1(Xi)=  - 27.8%. 
 
B) We study the effect of a GP asking the patient to make a new appointment if 
she does not get better vs. not asking the patient to make a new appointment, other 
variables remaining unchanged, and get 
1/1+e
-(2.263-2.158)=1/1+0.90= 0.526, thus there is a 52.6% probability that this GP for 
will choose Referral vs. Balancid/Zantac and P1(Xi*) = 52.6% 
The effect of the GP asking the patient to make a new appointment is a decrease in 
the probability by dP1(Xi)/dXinf
 =P1(X*i)-P1(Xi)=  - 37.9%. 
 
The probability of choosing triple therapy vs. Balancid/Zantac 




-(-5.918 +5.911*1+0.310*3 + 0.059*30 - 0.0004*900 + 0.006*45 - 0.035 – 0.444 + 0  - 0.683+ 0 + 0.286 - 
0.0003*35+ 0.001*90+0- 0 +0)
 =1/1+e
-(-5.918 + 5.911+0.930 + 1.77 –0.36 + 0.27 - 0.035 – 0.444  - 0.683+ 0.286 - 
0.0105+ 0.090)   60
=1/1+e
-(1.81) = 1/1 + 0.164= 0.859, thus it is a 85.9% probability for this GP to 
choose triple therapy vs. Balancid/Zantac and P1(Xi) =  85.9%. 
 
Effect of the result of HPRT 
When we study the effect of a GP receiving a negative vs. a positive 
laboratoryresult other variables remaining unchanged, we get 
1/1+e
-(1.81-5.918)=1/1+ 60.8= 0.016, thus it is a 1.6% for this GP to choose triple 
therapy vs. Balancid/Zantac and P1(Xi*) = 1.6%. 
The effect of HPRT is a decrease in the probability by  
dP1(Xi)/dXif
 =P1(Xi*)-P1(Xi)=  - 84.3%. 
 
Importance of lab. 
When we study the effect of a GP giving the importance of HPRT-test 5 points, 
increased from 3 points other variables remaining unchanged, we get 
1/1+e
-(1.81+0.31*2)=1/1+ 0.088= 0.919, thus it is a 91.9% for this GP to choose triple 
therapy vs. Balancid/Zantac and P1(Xi*) = 91.9%. 
The effect of HPRT is a increase in the probability by  
dP1(Xi)/dXif
 =P1(Xi*)-P1(Xi)=  + 6%. 
 
Effect of recommending sick leave  
When we study the effect of a GP not recommending sick leave vs. a GP 
recommending sick leave, other variables remaining unchanged, we get 
1/1+e
-(1.81 + 1.461)=1/1+0.038 = 0.963, thus it is a 96.3% for this GP to choose triple 
therapy vs. Balancid/Zantac and P1(Xi*) =96.3%   61
The effect of whether or not sick leave is recommended is an increase in the 
probability by  dP1(Xi)/dXinf
 =P1(X*i)-P1(Xi)= 10.4% 
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Table 1 Overview over the medical strategies chosen by the GPs  
Independ.variables 
Medical strategies 
GPs with HPRT 
Negative           Positive 
GPs without HPRT 
1.consultation*   Negative        Positive 
1. Balancid/Zantac  112 (56%)    8 ( 4%)  55 (71%)  14 (19%)   2 (2%) 
2. Referral    85 (42%)  101(53%)   22 (29%)  65 (81%)  44 (52%) 
3. Triple therapy      4 (2%)  83 (43%)    0 (0%)   0 (0%)  37 (46%) 
 *9 GPs chose ”no medical action” in addition to a serological test in the first consultation, but chose medical 
actions in the second consultation 
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Table 2 Descriptive statistics of the variables included.    
Variables Definition  With  HPRT 
Mean.  Std.dev 
Without HPRT 
Mean     Std.dev 
Sex  Binary variable:1 if male, 0 if female    0.806     0.762   
Age  Number of years   46.200  7.299  45.400  8.464 
Need of info  Need for information about the use of HPRT; Binary: 1 if 
some or a lot, 0 if none or only modest 
  0.642    0.429   
Type of info  The two most important information sources of HPRT. 
Binary variable; 1 if only suppliers info, 0 if other  
  0.517    0.607   
Group practice  Type of practice. Binary variable: 1 if group practice, 0 if 
solo practice  
  0.776    0.774   
Urban  Reference category for location of practice:  
Binary variable: 1 if inhab.>15000, other 0  
  0.632    0.500   
 Semi-Urban  Category for location of practice. Binary variable: 1if 
5000≤inhab.≤15000, 0 if other  
  0.209    0.321   
Rural  Category for location of practice 
Binary variable: 1 if inhab.<5000, 0 if other  
  0.159    0.179   
Consultations  Number of consultations per week  89.139  27.316  74.881  27.224 
Working hours.  Number of working hours per week  35.129    8.088  32.637  9.548 
Private practice  Binary:0=fixed salary, 1=are reimbursed  0.92    0.798   
Specialist  The GPs education. A number of courses are required to 
have a specialist certificate- 
Binary variable: 1 if specialist certificate, 0 if other  
  0.721    0.655   
Wait.upper endo.  Waiting time in weeks for upper endoscopy where the GP 
uses to refer 
  4.900    3.700  5.023  3.727 
Trav.upper endo.  Travelling time in hours for the patient (one way) for upper 
endoscopy where the GP usually  refers  
  1.015    3.495  0.778  0.918 
Pre-test-
probability 
The pre-test probability that Mrs Hansen's symptoms are 
due to a H.pylori infection 
49.459 20.515 48.085  20.866 
Importance of 
negative test 
The importance of HPRT-test on a scale from 1 to 10 
 
2.797 1.447 -  - 
Importance of 
positive test 
The importance of HPRT-test on a scale from 1 to 10  3.923  1.8  -  - 
Post-test-prob. 
negative test 
The post-test probability that Mrs Hansen's symptoms are 
due to a H.pylori infection 
16.492 17.170 15.809* 19.663 
Post-test-prob. 
positive test 
The post-test probability that Mrs Hansen's symptoms are 
due to a H.pylori infection 
76.166 10.016 79.669* 17.967 
Sick leave – neg  Binary:0= not sick leave, 1=sick leave  0.269    0.107*        
Sick leave – pos  Binary:0= not sick leave, 1=sick leave  0.318    0.100*   
New appointment 
Negative 
Binary:0= no appointm.1=new appointm  0.438    0.060*   
New appointment 
positive 
Binary:0= no appointm.1=new appointm.  0.477    0.071*   
Patient initiated 
appointm. – neg 
Binary:0= no appointm.1=new appointm.  0.468    0*   
Patient initiated 
appointm. – pos. 
Binary:0= no appointm.1=new appointm.  0.248    0.024*   
First consultation  Binary:0= no actions, Balancid/Zantac 1=referral  -  -  0.262   
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Table 3 Results of  the estimation of the model for GPs with HPRT - Reference; Balancid/Zantac 
Independent variables  Medical action  Standard Model 
Parameter                t-ratio 
Random effect 
Parameter             t-ratio 
Referral 1.630  0.911  2.290  1.023  Constant 
Triple therapy  -5.918 -2.210  - 7.643  -1.919 
Referral  2.847 (17.2)  6.213   3.139 (23)  5.576  Result of HPRT 
Triple therapy  5.911 (369)  7.939  6.874  (966)  4.640 
Referral  -0.088 (0.92)  -0.812  -0.107 (0.89)  -0.801  Importance of lab 
Triple therapy  0.310 (1.36)  2.213   0.483 (1.62)  2.042 
Referral  -0.030 (0.97)  -0.955  -0.038 (0.96)  -0.984  Pre-test-probability 
Triple therapy  0.059 (1.06)  1.251  0.078 (1.08)  1.280 
Referral  0.0004  (1.0004)  1.175  0.0005 (1.0005)  1.191  Pre-test-probability
2 
Triple therapy  -0.0004 (0.9996)  -0.922  -0.0006 (0.9994)  -1.004 
Referral  0.690 (1.99)  2.096  0.818 (2.26)  1.957  Type of info 
Triple therapy  0.867 (2.38)  1.947  1.064 (2.89)  1.881 
Referral  -1.097 (0.33)  -1.633  -1.378 (0.25)  -1.593  Private practice 
Triple therapy  0.286 (1.33)  0.306  0.591 (1.81)  0.465 
Referral  -1.744 (0.17)  -3.849  -2.126 (0.12)  -3.651  New appointment 
Triple therapy  -0.831 (0.43)  -1.472  -0.800 (0.51)  -1.065 
Referral  -2.158 (0.12)  -4.685  -2.664 (0.07)  -4.274  New appointment initiated by 
patient  Triple therapy  -1.051 (0.35)  -1.720  -1.166 (0.31)  -1.478 
Referral  0.755 (2.12)  2.009  0.838 (2.31)  1.806  Sick leave 
Triple therapy  1.461 (4.31)  2.983  1.853 (6.38)  2.529 
Referral  - -  1.169 2.859  Variance of the random effect 
Triple therapy  -  -  1.241  1.167 
Log-L   -348.8615    -346.0475   
Restricted Log-L        -490.7482   
McFaddens R
2   0.283    0.295   
McFaddens adjusted R
2   0.254    0.265   
Bold figures indicate that the effect is significant at 5% level, and figures in italics are significant at 10% level. 
The odds rates are given in parentheses. 
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Table 4 Results of the estimation of the model for GPs without HPRT - Reference: Balancid/Zantac 
Independent variables  Medical actions  Standard Model 
Parameter              t-ratio 
Random effect 
Parameter              t-ratio 
Referral -1.039 -0.287  -0.947 -0.258  Constant  
Triple therapy  -8.949 -1.928  -9.483 -1.974 
Referral  0.285 (1.33)  3.253  0.288 (1.33)  3.245  Post-test probability 
  Triple therapy  0.393 (1.48)  3.845  0.397 (1.48)  3.813 
Referral  -0.003 (0.997)  -3.143  -0.003 (0.997)  -3.138  Post-test probability
2 
Triple therapy  -0.003 (0.997)  -3.369 -0.003  (0.997)  -3.338 
Referral  1.450 1.403  1.483 1.407  First consultation 
Triple  therapy  1.057 0.909  1.117 0.935 
Referral  -2.035 (0.13)  -2.189  -2.058 (0.13)  -2.185  Semi-Urban 
Triple  therapy  -1.731 -1.654  -1.705 -1.602 
Referral  0.020 0.012  0.048 0.029  Rural 
Triple  therapy  0.912 0.509  1.048 0.571 
Referral -1.766 -1.113  -1.776 -1.113  Private practice 
Triple  therapy  -1.596 -0.838  -1.596 -0.838 
Waiting time  Referral  0.165 (1.18)  1.917  0.166  1.893 
Referral -0.823 -0.747  -0.813 -0.725  New appointment 
Triple  therapy  -1.373 -1.010  -1.421 -1.016 
Referral -  - 0.313  0.740  Variance of the random effect 
Triple therapy  -  -  0.361  0.527 
Log-L   -74.63944    - 74.16657   
Restricted Log-L    -    -152.7071   
McFaddens R
2   0.375    0.378   
McFaddens adjusted R
2   0.282    0.286   
Bold figures indicate that the effect is significant at 5% level, and figures in italics are significant at 10% level. 
The odds rate are given in parentheses 
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Table 5. The marginal effects of significant variables on the probability of certain medical 
actions of GPs – using HPRT 
Independent variables  Referral  
vs.Balancid/Zantac
   90.5% 
Triple therapy vs. 
Balancid/Zantac 
 85.9% 
Result of the HP-analysis 





Importance of lab. 3→ 5    +  6.0 
Not a new appointment → new appointment  - 27.8   
The patient is not asked to make a new 




Does not  → does recommend sick leave   +  10.4 
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Tables to the appendixes 
 





ulcus    Healthy carriers of the bacteria 
 1000  0,2   0.15     
           
  sens bact  spes. bact=1-healthy carriers of the bacteria 
 1  0,85        
           
 Ulcus  +  Ulcus  neg        
Bakt +  200  120        
Bakt -  0  680        
 200  800        
           
           
HPRT            
 sensitivity  specificity        
 0,85  0,8        
           
  Bact +; ulc+  Bact +; ulc -    Bact -, ulc-  Pred. Value 
positive test  170  102   136 0,416667   
negative 
test  30 18   544 0,949324   
 200  120   680    
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Table C.2 Overview for GPs with HPRT  
 
All results based on nonmissing observations. 
Stratification is based on TEST 
=============================================================================== 
Variable        Mean         Std.Dev.        Minimum         Maximum      Cases 
=============================================================================== 
------------------------------------------------------------------------------- 
Stratum is TEST     =     Negative  Obs.=   768.000, Sum of wts. =     768.000 
------------------------------------------------------------------------------- 
POSPRED   20.3750000      15.9786363      .000000000      100.000000        768 
POSTSAN   15.5661376      16.2491436      .000000000      100.000000        756 
------------------------------------------------------------------------------- 
Stratum is TEST     =     Positive  Obs.=   768.000, Sum of wts. =     768.000 
------------------------------------------------------------------------------- 
POSPRED   68.0416667      21.8387676      .000000000      100.000000        768 
POSTSAN   76.3078947      18.9247505      10.0000000      100.000000        760 
   8
Table C3 Overview for GPs without HPRT  
 
=============================================================================== 
Variable        Mean         Std.Dev.        Minimum         Maximum      Cases 
=============================================================================== 
------------------------------------------------------------------------------- 
Stratum is TEST     =    Negative  Obs.=   234.000, Sum of wts. =     234.000 
------------------------------------------------------------------------------- 
POSPRED   9.12820513      15.8293141      .000000000      100.000000        234 
POSTSAN   16.4066667      20.1566455      .000000000      90.0000000        225 
------------------------------------------------------------------------------- 
Stratum is TEST     =    Positive  Obs.=   234.000, Sum of wts. =     234.000 
------------------------------------------------------------------------------- 
POSPRED   76.5641026      19.9182383      .000000000      100.000000        234 
POSTSAN   79.5743243      18.0394896      5.00000000      100.000000        222   9
Table D.1 Results of  the estimation of the model for GPs with HPRT- Reference: Balancid/Zantac 
Independent variables  Medical action  Standard Model 
Parameter                t-ratio 
Random effect 
Parameter             t-ratio 
Referral  1.630 0.911  2.290 1.023  Constant 
Triple therapy  -5.918 -2.210  - 7.643  -1.919 
Referral  2.847 (17.2)  6.213   3.139 (23)  5.576  Result of HPRT 
Triple therapy  5.911 (369)  7.939  6.874  (966)  4.640 
Referral  -0.088 (0.92)  -0.812  -0.107 (0.89)  -0.801  Importance of lab 
Triple therapy  0.310 (1.36)  2.213   0.483 (1.62)  2.042 
Referral  -0.030 (0.97)  -0.955  -0.038 (0.96)  -0.984  Pre-test-probability 
Triple therapy  0.059 (1.06)  1.251  0.078  1.280 
Referral 0.0004    1.175  0.0005 1.191  Pre-test-probability
2 
Triple  therapy  -0.0004 -0.922  -0.0006 -1.004 
Referral  0.003 0.128  0.003 0.102  Age 
Triple therapy  0.006  0.179  -0.002  -0.044 
Referral -0.125 -0.284  -0.069 -0.125  Sex 
Triple  therapy  -0.035 -0.058  -0.082 -0.109 
Referral -0.422 -1.186  -0.477 -1.075  Need of info 
Triple  therapy  -0.444 -0.907  -0.635 -1.007 
Referral  0.690 (1.99)  2.096  0.818 (2.26)  1.957  Type of info 
Triple therapy  0.867 (2.38)  1.947  1.064 (2.89)  .1881 
Referral -0.351 -0.858  -0.411 -0.804  Group practice 
Triple  therapy  -0.683 -1.227  -0.888 -1.255 
Referral -0.231 -0.556  -0.294 -0.572  Semi-Urban 
Triple therapy  -0.107  -0.192  0.018  0.026 
Referral  0.172 0.354  0.203 0.341  Rural 
Triple  therapy  -0.259 -0.377  -0.306 -0.365 
Referral -1.097   -1.633  -1.378 -1.593  Private practice 
Triple  therapy  0.286 0.306  0.591 0.465 
Referral -0.013 -0.369  -0.025 -0.502  Travelling time 
Triple therapy  -  - -  - 
Referral  0.008 0.235  0.005 0.107  Waiting time  
Triple therapy  -  -  -  - 
Referral  0.009 0.380  0.011 0.374  Working hours 
Triple therapy  -0.0003  -0.009  0.001  0.032 
Referral  0.002 0.215  0.002 0.162  Consultations 
Triple  therapy  0.001 0.067  0.001 0.074 
Referral  0.315 0.768  0.423 0.824  Specialist 
Triple  therapy  -0.229 -0.417  -0.376 -0.538 
Referral  -1.744 (0.17)  -3.849  -2.126 (0.12)  -3.651  New appointment 
Triple therapy  -0.831 (0.43)  -1.472  -0.800 (0.51)  -1.065 
Referral  -2.158 (0.12)  -4.685  -2.664 (0.07)  -4.274  New appointment initiated by 
patient  Triple therapy  -1.051 (0.35)  -1.720  -1.166 (0.31)  -1.478 
Referral  0.755 (2.12)  2.009  0.838 (2.31)  1.806  Sick leave 
Triple therapy  1.461 (4.31)  2.983  1.853 (6.38)  2.529 
Referral -  - 1.169 2.859  Variance of the random effect 
Triple therapy  -  -  1.241  1.167 
Log-L   -348.8615    -346.0475   
Restricted Log-L        -490.7482   
McFaddens R
2   0.283    0.295   
McFaddens adjusted R
2   0.254    0.265   
Bold figures indicate that the effect is significant at 5% level, and figures in italics at 10%level.   10
 
Table D.2 Results from the estimation of the model for GPs without HPRT  - Reference; 
Balancid/Zantac 
Independent variables  Medical actions  Standard Model 
Parameter              t-ratio 
Random effect 
Parameter              t-ratio 
Referral -1.039 -0.287  -0.947 -0.258  Constant  
Triple therapy  -8.949 -1.928  -9.483 -1.974 
Referral  0.285 (1.33)  3.253  0.288 (1.33)  3.245  Post-test probability 
  Triple therapy  0.393 (1.48)  3.845  0.397 (1.48)  3.813 
Referral  -0.003 (0.997)  -3.143  -0.003 (0.997)  -3.138  Post-test probability
2 
Triple therapy  -0.003 (0.997)  -3.369  -0.003 (0.997)  -3.338 
Referral  1.450 1.403  1.483 1.407  First consultation 
Triple  therapy  1.057 0.909  1.117 0.935 
Referral  0.006 0.092  0.005 0.079  Age 
Triple  therapy  0.049 0.669  0.054 0.712 
Referral  0.770 0.824  0.794 0.832  Sex 
Triple  therapy  1.402 1.236  1.448 1.238 
Referral  0.257 0.344  0.241 0.319  Need of info 
Triple therapy  1.489  1.687  1.577 1.721 
Referral -0.458 -0.556  -0.450 -0.539  Type of info 
Triple  therapy  -0.608 -0.616  -0.643 -0.640 
Referral -0.920 -0.920  -0.946 -0.929  Group practice 
Triple  therapy  -1.684 -1.386  -1.741 -1.386 
Referral  -2.035 (0.13)  -2.189  -2.058 (0.13)  -2.185  Semi-Urban 
Triple  therapy  -1.731 -1.654  -1.705 -1.602 
Referral  0.020 0.012  0.048 0.029  Rural 
Triple  therapy  0.912 0.509  1.048 0.571 
Referral -1.766 -1.113  -1.776 -1.113  Private practice 
Triple  therapy  -1.596 -0.838  -1.596 -0.838 
Referral -0.022 -0.032  -0.083 -0.115  Travelling time 
Triple therapy  -  - -  - 
Referral 0.165  (1.18)  1.917  0.166  1.893  Waiting time 
Triple therapy  -  -  -  - 
Referral -0.008 -0.160  -0.008 -0.167  Working hours 
Triple  therapy  -0.006 -0.107  -0.008 -0.131 
Referral  0.038 1.504  0.038 1.497  Consultations 
Triple  therapy  0.044 1.606  0.045 1.595 
Referral -0.932 -1.001  -0.953 -1.003  Specialist 
Triple  therapy  -0.821 -0.752  -0.816 -0.731 
Referral -0.823 -0.747  -0.813 -0.725  New appointment 
Triple  therapy  -1.373 -1.010  -1.421 -1.016 
Referral -  - 0.313  0.740  Variance of the random effect 
Triple therapy  -  -  0.361  0.527 
Log-L   -74.63944    - 74.16657   
Restricted Log-L        -152.7071   
McFaddens R
2   0.375    0.378   
McFaddens adjusted R
2   0.282    0.286   
Bold figures indicate that the effect is significant at 5% level, and  figures in italics are significant at 10%level. 